Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
19.74 SEK | +8.22% | +19.93% | +27.68% |
Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
Apr. 17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
Sales 2024 * | 617M 57M | Sales 2025 * | 788M 72.78M | Capitalization | 628M 58.05M |
---|---|---|---|---|---|
Net income 2024 * | -107M -9.89M | Net income 2025 * | -28M -2.59M | EV / Sales 2024 * | 1.49 x |
Net Debt 2024 * | 289M 26.7M | Net Debt 2025 * | 201M 18.57M | EV / Sales 2025 * | 1.05 x |
P/E ratio 2024 * |
-5.86
x | P/E ratio 2025 * |
-22
x | Employees | 116 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.49% |
Latest transcript on Orexo AB
1 day | +8.22% | ||
1 week | +19.93% | ||
Current month | +16.80% | ||
1 month | +25.10% | ||
3 months | +34.29% | ||
6 months | +28.68% | ||
Current year | +27.68% |
Managers | Title | Age | Since |
---|---|---|---|
Nikolaj Sørensen
CEO | Chief Executive Officer | 52 | 11-09-30 |
Fredrik Järrsten
DFI | Director of Finance/CFO | 57 | 22-08-31 |
Edward Kim
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 19-04-10 | |
James Noble
CHM | Chairman | 65 | 20-04-15 |
Director/Board Member | 62 | 01-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 19.74 | +8.22% | 73 865 |
24-05-03 | 18.24 | +6.05% | 31,245 |
24-05-02 | 17.2 | +1.78% | 33,667 |
24-04-30 | 16.9 | +2.67% | 14,135 |
24-04-29 | 16.46 | -0.48% | 3,679 |
Delayed Quote Nasdaq Stockholm, May 06, 2024 at 06:55 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.68% | 58.17M | |
+5.73% | 71.19B | |
+12.55% | 9.3B | |
-13.75% | 5.01B | |
+42.38% | 4.47B | |
+4.51% | 3.96B | |
+21.10% | 2.44B | |
-19.05% | 2.41B | |
-28.72% | 2.23B | |
+11.13% | 2.02B |
- Stock Market
- Equities
- ORX Stock